

For Immediate Release

Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of *Journal of the Science of Healing Outcomes*

Four-month study detailing effects of treatment of HIV-positive individuals with American Biotech Labs (ABL) ASAP 10 treatment indicates significant improvement in the condition of the subjects after treatment; in-vitro laboratory work shows that ABL nanosilver particles can block entry of the virus into cells, "eventually destroying the virus"

ALPINE, UT (August 29, 2008) – American Biotech Labs, developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology™, today announced that a preliminary study of the effect of the company's ASAP 10 treatment on HIV-positive individuals has been published in the first issue of the *Journal of the Science of Healing Outcomes* (JSHO; www.thejsho.com/pdf/Effect.pdf). JSHO is a scholarly health journal that publishes compelling new medical research data and reports.

The study was conducted over four months with seven HIV-positive patients, each of whom was administered 15 ml of ABL ASAP 10 ppm (parts per million) four times daily. As a result of the ABL treatment, "Clinically, (the patients) were 100 percent fit and were feeling much better after the treatment period," said Dr. B.M. Hegde, world-renowned cardiologist and editor of JSHO.

During the course of the therapy, the patients experienced an average body weight gain of eight kilograms (17.6 pounds) and an average T-lymphocyte count increase of 180 per micro-liter (39.52 percent).

One of the study's most significant findings, said Hegde, was the effect of ABL ASAP on HIV, the AIDS-causing virus. "Our recent laboratory work of the effect of nano silver in vitro on the ... virus did show that the nanosilver particles could bind to (HIV) and could potentially block the viral entry into cells, eventually destroying the virus."

Hegde added, "Now that we have the laboratory results of the drug's efficacy and safety, we are planning a large scale controlled study of the application to HIV positive individuals in the near future."

About American Biotech Labs

American Biotech Labs (ABL; www.AmericanBiotechLabs.com), founded in 1998, utilizes patented processes and SilverSol Technology™ to create singularly powerful and effective nano-catalytic silver products. In extensive testing performed by a variety of respected laboratories and researchers, ABL's silver hydrosol has consistently demonstrated the ability, without any known toxic side effects, to destroy a wide range of bacteria, viruses, yeast, and molds. ABL products have been approved by the U.S. EPA as a disinfectant for dental water lines, and as a surface disinfectant for bacteria, yeast and mold in hospital, residential, commercial and industrial settings. The company's products are sold worldwide at health food stores and by medical professionals under the Silver Biotics® and ASAP Solution® brands and through a variety of private labels.

###

Press Contact:

Kimball Thomson
Next Phase Communications (for American Biotech Labs)
801.918.3637
kthomson@npcomm.com